Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer.

By Yumi Yamamoto, R. Gaynor. Journal of Clinical Investigation, 2001

1,694 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/c7d7683f318640d29cdafe059a2dc2d25d7dfe30

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. A. Baldwin
2. Xianyang Yio
3. S. Itzkowitz
4. T. Mogensen
5. P. Moynagh

In Molecular Biology

1. A. Baldwin
2. Xianyang Yio
3. S. Itzkowitz
4. T. Mogensen
5. P. Moynagh

In Oncology

1. A. Baldwin
2. T. Mogensen
3. P. Moynagh

Citations in the corpus

• Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. (2004, background): “For example, the transcription factor NF- B can stimulate iNOS to generate NO and COX-2 to generate prostanoids that have proinflammatory and carcinogenic effects (88).”
• Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB (2001, background): “Interestingly, aspirin and sulindac both have been reported to inhibit the activation of the IκB kinase complex (39).”
• The NF-κB pathway (2005, background): “Dysregulation of this transcription factor can thus lead to inflammatory and autoimmune diseases (Yamamoto and Gaynor, 2001).”